New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:02 EDTCRISCuris appoints Fattaey CEO, president
Curis announced the appointment of Ali Fattaey as the company's president and CEO and as a member of its Board of Directors. Fattaey formerly served as the company's president and COO. He will succeed Dan Passeri following his resignation from the position of CEO, which was also announced. Passeri has been appointed vice chairman of Curis' Board of Directors and will also serve as a strategic advisor to Curis.
News For CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:05 EDTCRISCuris doses first patient in CUDC-907 Phase 1 trial
Curis announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, enzymes that is currently under investigation in the first-in-human Phase 1 clinical study in patients with relapsed or refractory lymphomas and multiple myeloma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use